<p>Nanovery 的首席執行官 Jurek Kozyra 加入主持人 Karla Jo Helms，在《Disruption Interruption》播客中討論分子醫學的革命。Kozyra 揭示了 DNA 納米機器人和人工智能如何將診斷等待時間從幾天縮短到幾小時，並加速藥物開發，可能縮短十年才能上市的救命治療的過程。</p>
<p>, /PRNewswire/ -- 將新藥從發現到上市的過程是一場艱苦的馬拉松，通常需要 10 到 15 年的研究、測試和監管批准。根據最近的數據，創新藥物的臨牀開發時間在過去十年中保持停滯，平均持續時間約為 8 年。Nanovery 的創始人兼首席執行官 Jurek Kozyra 在最新一期的《Disruption Interruption podcast》中與主持人 Karla Jo Helms 坐下來，解釋他是如何拆除這些障礙的。Kozyra 討論了 DNA 納米技術與人工智能的融合如何創造出一種新的 “寡核苷酸治療” 時代，能夠針對疾病的根本機制。</p>
<p>繼續閲讀</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>DI: 第 212 集</p>
<p>&#34;如果你能非常具體地靶向 mRNA，那麼理論上你可以治癒所有疾病，&#34; Kozyra 説。&#34;這就是為什麼這個領域現在如此令人興奮。&#34;</p>
<p><strong>傳統醫學的停滯</strong></p>
<p>幾個世紀以來，醫學一直採用 “鎖和鑰匙” 模型，尋找能夠修復缺陷蛋白質的分子。然而，這種方法使許多疾病無法治療，因為科學家無法找到合適的分子來匹配目標。此外，診斷過程仍然危險地緩慢；傳統實驗室測試的結果可能需要長達兩天才能返回——在藥物過量等緊急情況下，這種延遲可能是致命的。</p>
<p>製藥公司也在與時間賽跑。&#34;製藥公司在與 20 年的專利賽跑，而藥物開發通常需要超過 10 年，&#34; Kozyra 解釋道。&#34;許多疾病無法治癒，因為我們無法找到能夠修復蛋白質的合適分子。但這裏的希望在於，你實際上可以治癒所有疾病，因為所有蛋白質都來自 mRNA。&#34;</p>
<p>這種低效導致數十億美元的成本和新藥 90% 的失敗率，限制了患者獲得救命創新的機會。</p>
<p><strong>納米機器人：快速檢測的未來</strong></p>
<p>Kozyra 的解決方案在於 DNA 納米機器人——自組裝的機器，能夠在 2-4 小時內檢測血液樣本中的疾病，這比傳統方法所需的時間少得多。與科幻小説中的金屬機器人不同，這些生物機器被設計為在遇到特定的 DNA 或 RNA 分子時產生熒光信號，從而實現快速、準確的現場診斷。</p>
<p>&#34;我們正在創造自組裝成結構或動態設備的納米機器人，&#34; Kozyra 表示。&#34;你只需將它們添加到樣本中，讓它們找到合適的標記，然後它們開始產生信號。如果你能檢測到它，你就知道你的樣本中到底有什麼。&#34;</p>
<p>該技術在一項涉及 170 個患者樣本的醫院研究中已經證明了其價值。&#34;在臨牀環境中，我們的技術在僅僅兩小時內提供了與傳統測試相同或更好的結果，而不是兩天，&#34; Kozyra 指出。&#34;這對緊急情況下需要立即答案的情況來説是一個遊戲規則的改變。&#34;</p>
<p><strong>鏈接</strong> 顛覆生物技術：DNA 納米機器人如何重寫藥物發現的規則，Jurek Kozyra 主講</p>
<p>https://omny.fm/shows/disruption-interruption/disrupting-biotech-how-dna-nanorobots-are-rewriting-the-rules-of-drug-discovery-with-jurek-kozyra</p>
<p><strong>LinkedIn:</strong> https://www.linkedin.com/in/j3ny/</p>
<p><strong>公司網站：</strong> https://nanovery.co.uk</p>
<p>《Disruption Interruption》是一個播客，你將聽到當今最大行業顛覆者的聲音。瞭解是什麼激勵他們帶來創新，以及他們是如何克服反對意見以實現採納的。</p>
<p>《Disruption Interruption》可以在蘋果應用商店和 Spotify 上收聽。</p>
<p><strong>關於 Disruption Interruption™</strong></p>
<p>顛覆正在以前所未有的規模發生，影響着各個行業——醫療科技、金融、IT、電子商務、運輸、物流等——而 COVID 使他們的時間表提前了整整十年或更長時間。但這些顛覆者是誰，他們何時説過：“夠了！我受夠了！”？是時候與主持人 Karla Jo &#34;KJ&#34; Helms 一起顛覆和打斷了，KJ 是一位資深的傳播顛覆者。KJ 採訪那些正在顛覆其行業並改變已經過時的經濟網絡的強者，揭示行業叛逆者和安靜革命者的秘密，這些人揭示了改變我們經濟市場和生活的共同特徵——以及不那麼常見的特徵。訪問世界上那些儘管背後有箭仍然堅持成功的關鍵先驅者，網址是 www.disruption-interruption.com。</p>
<p><strong>關於 Jurek Kozyra</strong></p>
<p>Jurek Kozyra 是一位開創性的深科技企業家和研究人員，在 DNA 納米技術、人工智能和分子納米機器的交叉領域擁有超過十年的經驗。作為 Nanovery 的創始人兼首席執行官，Jurek 正在引領分子醫學的變革，開發加速下一代 RNA 治療藥物發現和特徵化的生物分析平台。Nanovery 已籌集超過 700 萬美元，並與全球製藥公司建立了合作關係，正朝着顛覆疾病診斷和治療的方向邁進。</p>
<p>在創辦 Nanovery 之前，Jurek 在學術界磨練了他的專業知識，設計基於 DNA 的納米設備，並開創了推動計算和納米生物學邊界的算法。他的多學科方法使他能夠將突破性的科學轉化為商業生物技術解決方案，彌合研究與現實世界應用之間的差距。</p>
<p>在 Nanovery，Jurek 的使命是推動 RNA 藥物生物分析的創新，從高通量檢測開發到先進的數據分析，使複雜疾病的治療更加安全和有效。他的工作引起了領先學術界、行業合作伙伴和跨職能團隊的關注，鞏固了他在生物技術領域的遠見卓識。</p>
<p><strong>關於 Karla Jo Helms</strong></p>
<p>Karla Jo Helms 是 JOTO PR Disruptors™的首席傳播官和反公關戰略家。Karla Jo 親身體驗了當數百萬美元處於風險之中時，商業是多麼無情——以及公眾輿論的控制往往決定了一家公司是被愉快選擇，還是被殘酷拒絕。作為危機管理的校友，Karla Jo 與訴訟律師、私人調查員和媒體合作，幫助恢復企業的良好聲譽，使其重新贏得公眾的信任——Karla Jo 秉持一次性做對的倫理，不依賴第二次機會，竭盡所能追求卓越。Helms 在全球範圍內就公共關係發表演講，探討公關行業如何迷失方向，以及在正確的手中，企業如何利用反公關的力量來推動市場並影響市場認知。</p>
<p><strong>參考文獻</strong></p>
<ol>
<li>Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., &amp; Southall, N. (2023). 創新藥物的臨牀開發時間。《自然評論：藥物發現》，21(11)。doi.org/10.1038/d41573-021-00190-9</li>
</ol>
<p>媒體諮詢：</p>
<p>Karla Jo Helms</p>
<p>JOTO PR™</p>
<p>727-777-4629</p>
<p>來源：Disruption Interruption</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE1Jk5ld3NJdGVtSWQ9Rkw2NDY1OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTUxNjA2UFJfTkVXU19VU1BSX19fX19GTDY0NjU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE1Jk5ld3NJdGVtSWQ9Rkw2NDY1OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTUxNjA2UFJfTkVXU19VU1BSX19fX19GTDY0NjU4"/></p>

醫療業 3 倍做多 - Direxion

NNOX

<p>Nanovery 的首席執行官 Jurek Kozyra 在 Disruption Interruption 播客中討論了 DNA 納米機器人和人工智能如何革新分子醫學。這些創新旨在將藥物開發時間從 10-15 年縮短到僅幾個小時，可能通過靶向 mRNA 來治癒疾病。Kozyra 強調了傳統醫學的低效，並指出納米機器人能夠在 2-4 小時內檢測血樣中的疾病，顯著快於傳統方法。這項技術在臨牀環境中顯示出良好的結果，標誌着快速診斷和藥物發現的重大進展</p>

<p><em>Jurek Kozyra, CEO of Nanovery, joins host Karla Jo Helms on the Disruption Interruption podcast to discuss revolutionizing molecular medicine. Kozyra reveals how DNA nanorobots and AI are reducing diagnostic wait times from days to hours and accelerating drug development, potentially shortening the decade-long journey to market life-saving treatments.</em></p>
<div class="lb-trans"><p>Nanovery 的首席執行官 Jurek Kozyra 加入主持人 Karla Jo Helms，在《Disruption Interruption》播客中討論分子醫學的革命。Kozyra 揭示了 DNA 納米機器人和人工智能如何將診斷等待時間從幾天縮短到幾小時，並加速藥物開發，可能縮短十年才能上市的救命治療的過程。</p>
</div><p>, /PRNewswire/ -- Bringing a new drug from discovery to market is a grueling marathon that typically requires 10–15 years of research, testing, and regulatory approval. According to recent data, clinical development times for innovative drugs have remained stagnant over the last decade, with a median duration of around 8 years. Jurek Kozyra, founder and CEO of Nanovery, sits down with host Karla Jo Helms on the latest episode of the <em>Disruption Interruption podcast</em> to explain how he is dismantling these barriers. Kozyra discusses how the convergence of DNA nanotechnology and AI is creating a new era of &#34;oligo therapeutics&#34; capable of targeting the underlying mechanisms of disease.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 將新藥從發現到上市的過程是一場艱苦的馬拉松，通常需要 10 到 15 年的研究、測試和監管批准。根據最近的數據，創新藥物的臨牀開發時間在過去十年中保持停滯，平均持續時間約為 8 年。Nanovery 的創始人兼首席執行官 Jurek Kozyra 在最新一期的《Disruption Interruption podcast》中與主持人 Karla Jo Helms 坐下來，解釋他是如何拆除這些障礙的。Kozyra 討論了 DNA 納米技術與人工智能的融合如何創造出一種新的 “寡核苷酸治療” 時代，能夠針對疾病的根本機制。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>繼續閲讀</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>DI: Episode 212</p>
<div class="lb-trans"><p>DI: 第 212 集</p>
</div><p>&#34;If you can target mRNA very specifically, that means that in theory, you could potentially cure all diseases,&#34; says Kozyra. &#34;That's why this area is so exciting right now.&#34;</p>
<div class="lb-trans"><p>&#34;如果你能非常具體地靶向 mRNA，那麼理論上你可以治癒所有疾病，&#34; Kozyra 説。&#34;這就是為什麼這個領域現在如此令人興奮。&#34;</p>
</div><p><strong>The Stagnation of Traditional Medicine</strong></p>
<div class="lb-trans"><p><strong>傳統醫學的停滯</strong></p>
</div><p>For centuries, medicine has operated on a &#34;lock and key&#34; model, hunting for molecules that can fix defective proteins. However, this approach leaves many diseases untreated simply because scientists cannot find the right molecule to fit the target. Furthermore, the diagnostic process remains dangerously slow; traditional lab tests can take up to two days to return results—a delay that can be fatal in emergency situations like drug overdoses.</p>
<div class="lb-trans"><p>幾個世紀以來，醫學一直採用 “鎖和鑰匙” 模型，尋找能夠修復缺陷蛋白質的分子。然而，這種方法使許多疾病無法治療，因為科學家無法找到合適的分子來匹配目標。此外，診斷過程仍然危險地緩慢；傳統實驗室測試的結果可能需要長達兩天才能返回——在藥物過量等緊急情況下，這種延遲可能是致命的。</p>
</div><p>Pharmaceutical companies are also racing against the clock. &#34;Pharma companies are racing against 20-year patents while drugs take over 10 years to develop,&#34; explains Kozyra. &#34;A lot of diseases cannot be cured because we cannot find the right molecule that will fix the protein. But the promise here is that you can actually cure potentially all diseases because all proteins come from mRNA.&#34;</p>
<div class="lb-trans"><p>製藥公司也在與時間賽跑。&#34;製藥公司在與 20 年的專利賽跑，而藥物開發通常需要超過 10 年，&#34; Kozyra 解釋道。&#34;許多疾病無法治癒，因為我們無法找到能夠修復蛋白質的合適分子。但這裏的希望在於，你實際上可以治癒所有疾病，因為所有蛋白質都來自 mRNA。&#34;</p>
</div><p>This inefficiency results in billions of dollars in costs and a 90% failure rate for new drugs, limiting patient access to life-saving innovations.</p>
<div class="lb-trans"><p>這種低效導致數十億美元的成本和新藥 90% 的失敗率，限制了患者獲得救命創新的機會。</p>
</div><p><strong>Nanorobots: The Future of Rapid Detection</strong></p>
<div class="lb-trans"><p><strong>納米機器人：快速檢測的未來</strong></p>
</div><p>Kozyra's solution lies in DNA nanorobots—self-assembling machines that can detect diseases in blood samples within 2-4 hours, a fraction of the time required by traditional methods. Unlike the metallic robots of science fiction, these biological machines are designed to produce fluorescent signals when they encounter specific DNA or RNA molecules, enabling rapid, accurate point-of-care diagnostics.</p>
<div class="lb-trans"><p>Kozyra 的解決方案在於 DNA 納米機器人——自組裝的機器，能夠在 2-4 小時內檢測血液樣本中的疾病，這比傳統方法所需的時間少得多。與科幻小説中的金屬機器人不同，這些生物機器被設計為在遇到特定的 DNA 或 RNA 分子時產生熒光信號，從而實現快速、準確的現場診斷。</p>
</div><p>&#34;We are creating nanorobots that self-assemble into structures or dynamic devices,&#34; Kozyra states. &#34;You simply add them to the sample, let them find the right markers, and they start producing a signal. If you can detect it, you know exactly what is in your sample.&#34;</p>
<div class="lb-trans"><p>&#34;我們正在創造自組裝成結構或動態設備的納米機器人，&#34; Kozyra 表示。&#34;你只需將它們添加到樣本中，讓它們找到合適的標記，然後它們開始產生信號。如果你能檢測到它，你就知道你的樣本中到底有什麼。&#34;</p>
</div><p>The technology has already proven its worth in a hospital study involving 170 patient samples. &#34;In a clinical setting, our technology delivered the same or better results than traditional tests in just two hours instead of two days,&#34; Kozyra notes. &#34;This is a gamechanger for emergency situations where immediate answers are critical.&#34;</p>
<div class="lb-trans"><p>該技術在一項涉及 170 個患者樣本的醫院研究中已經證明了其價值。&#34;在臨牀環境中，我們的技術在僅僅兩小時內提供了與傳統測試相同或更好的結果，而不是兩天，&#34; Kozyra 指出。&#34;這對緊急情況下需要立即答案的情況來説是一個遊戲規則的改變。&#34;</p>
</div><p><strong>Links</strong> Disrupting Biotech: How DNA Nanorobots Are Rewriting the Rules of Drug Discovery, with Jurek Kozyra</p>
<div class="lb-trans"><p><strong>鏈接</strong> 顛覆生物技術：DNA 納米機器人如何重寫藥物發現的規則，Jurek Kozyra 主講</p>
</div><p>https://omny.fm/shows/disruption-interruption/disrupting-biotech-how-dna-nanorobots-are-rewriting-the-rules-of-drug-discovery-with-jurek-kozyra</p>
<div class="lb-trans"><p>https://omny.fm/shows/disruption-interruption/disrupting-biotech-how-dna-nanorobots-are-rewriting-the-rules-of-drug-discovery-with-jurek-kozyra</p>
</div><p><strong>LinkedIn:</strong> https://www.linkedin.com/in/j3ny/</p>
<div class="lb-trans"><p><strong>LinkedIn:</strong> https://www.linkedin.com/in/j3ny/</p>
</div><p><strong>Company Website:</strong> https://nanovery.co.uk</p>
<div class="lb-trans"><p><strong>公司網站：</strong> https://nanovery.co.uk</p>
</div><p>Disruption Interruption is the podcast where you will hear from today's biggest Industry Disruptors. Learn what motivated them to bring about innovation and how they overcame opposition to adoption.</p>
<div class="lb-trans"><p>《Disruption Interruption》是一個播客，你將聽到當今最大行業顛覆者的聲音。瞭解是什麼激勵他們帶來創新，以及他們是如何克服反對意見以實現採納的。</p>
</div><p>Disruption Interruption can be listened to in Apple's App Store and Spotify.</p>
<div class="lb-trans"><p>《Disruption Interruption》可以在蘋果應用商店和 Spotify 上收聽。</p>
</div><p><strong>About Disruption Interruption™</strong></p>
<div class="lb-trans"><p><strong>關於 Disruption Interruption™</strong></p>
</div><p>Disruption is happening on an unprecedented scale, impacting all manner of industries— MedTech, Finance, IT, eCommerce, shipping, logistics, and more—and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, &#34;THAT'S IT! I'VE HAD IT!&#34;? Time to Disrupt and Interrupt with host Karla Jo &#34;KJ&#34; Helms, veteran communications disruptor. KJ interviews badasses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits—and not-so-common—that are changing our economic markets… and lives. Visit the world's key pioneers that persist to success, despite arrows in their backs at www.disruption-interruption.com.</p>
<div class="lb-trans"><p>顛覆正在以前所未有的規模發生，影響着各個行業——醫療科技、金融、IT、電子商務、運輸、物流等——而 COVID 使他們的時間表提前了整整十年或更長時間。但這些顛覆者是誰，他們何時説過：“夠了！我受夠了！”？是時候與主持人 Karla Jo &#34;KJ&#34; Helms 一起顛覆和打斷了，KJ 是一位資深的傳播顛覆者。KJ 採訪那些正在顛覆其行業並改變已經過時的經濟網絡的強者，揭示行業叛逆者和安靜革命者的秘密，這些人揭示了改變我們經濟市場和生活的共同特徵——以及不那麼常見的特徵。訪問世界上那些儘管背後有箭仍然堅持成功的關鍵先驅者，網址是 www.disruption-interruption.com。</p>
</div><p><strong>About Jurek Kozyra</strong></p>
<div class="lb-trans"><p><strong>關於 Jurek Kozyra</strong></p>
</div><p>Jurek Kozyra is a pioneering deep-tech entrepreneur and researcher with over a decade of experience at the intersection of DNA nanotechnology, AI, and molecular nanomachines. As the founder and CEO of Nanovery, Jurek is leading the charge in transforming molecular medicine by developing bioanalytical platforms that accelerate the discovery and characterization of next-generation RNA therapeutics. With more than $7 million raised and partnerships with global pharmaceutical companies, Nanovery is on track to revolutionize how diseases are diagnosed and treated.</p>
<div class="lb-trans"><p>Jurek Kozyra 是一位開創性的深科技企業家和研究人員，在 DNA 納米技術、人工智能和分子納米機器的交叉領域擁有超過十年的經驗。作為 Nanovery 的創始人兼首席執行官，Jurek 正在引領分子醫學的變革，開發加速下一代 RNA 治療藥物發現和特徵化的生物分析平台。Nanovery 已籌集超過 700 萬美元，並與全球製藥公司建立了合作關係，正朝着顛覆疾病診斷和治療的方向邁進。</p>
</div><p>Before founding Nanovery, Jurek honed up his expertise in academia, designing DNA-based nanodevices and pioneering algorithms that pushed the boundaries of computation and nanoscale biology. His multidisciplinary approach has enabled him to translate breakthrough science into commercial biotech solutions, bridging the gap between research and real-world applications.</p>
<div class="lb-trans"><p>在創辦 Nanovery 之前，Jurek 在學術界磨練了他的專業知識，設計基於 DNA 的納米設備，並開創了推動計算和納米生物學邊界的算法。他的多學科方法使他能夠將突破性的科學轉化為商業生物技術解決方案，彌合研究與現實世界應用之間的差距。</p>
</div><p>At Nanovery, Jurek's mission is to drive innovation in the bioanalysis of RNA drugs, from high-throughput assay development to advanced data analytics, enabling safer and more effective treatments for complex diseases. His work has garnered attention from leading academics, industry partners, and cross-functional teams, solidifying his reputation as a visionary in the biotech space.</p>
<div class="lb-trans"><p>在 Nanovery，Jurek 的使命是推動 RNA 藥物生物分析的創新，從高通量檢測開發到先進的數據分析，使複雜疾病的治療更加安全和有效。他的工作引起了領先學術界、行業合作伙伴和跨職能團隊的關注，鞏固了他在生物技術領域的遠見卓識。</p>
</div><p><strong>About Karla Jo Helms</strong></p>
<div class="lb-trans"><p><strong>關於 Karla Jo Helms</strong></p>
</div><p>Karla Jo Helms is the Chief Evangelist and Anti-PR® Strategist for JOTO PR Disruptors™. Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line — and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill into the good graces of public opinion — Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception.</p>
<div class="lb-trans"><p>Karla Jo Helms 是 JOTO PR Disruptors™的首席傳播官和反公關戰略家。Karla Jo 親身體驗了當數百萬美元處於風險之中時，商業是多麼無情——以及公眾輿論的控制往往決定了一家公司是被愉快選擇，還是被殘酷拒絕。作為危機管理的校友，Karla Jo 與訴訟律師、私人調查員和媒體合作，幫助恢復企業的良好聲譽，使其重新贏得公眾的信任——Karla Jo 秉持一次性做對的倫理，不依賴第二次機會，竭盡所能追求卓越。Helms 在全球範圍內就公共關係發表演講，探討公關行業如何迷失方向，以及在正確的手中，企業如何利用反公關的力量來推動市場並影響市場認知。</p>
</div><p><strong>References</strong></p>
<div class="lb-trans"><p><strong>參考文獻</strong></p>
</div><ol>
<li>Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., &amp; Southall, N. (2023). Clinical development times for innovative drugs. Nature Reviews Drug Discovery, 21(11). doi.org/10.1038/d41573-021-00190-9</li>
</ol>
<div class="lb-trans"><ol>
<li>Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., &amp; Southall, N. (2023). 創新藥物的臨牀開發時間。《自然評論：藥物發現》，21(11)。doi.org/10.1038/d41573-021-00190-9</li>
</ol>
</div><p>Media Inquiries:</p>
<div class="lb-trans"><p>媒體諮詢：</p>
</div><p>Karla Jo Helms</p>
<div class="lb-trans"><p>Karla Jo Helms</p>
</div><p>JOTO PR™</p>
<div class="lb-trans"><p>JOTO PR™</p>
</div><p>727-777-4629</p>
<div class="lb-trans"><p>727-777-4629</p>
</div><p>SOURCE Disruption Interruption</p>
<div class="lb-trans"><p>來源：Disruption Interruption</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE1Jk5ld3NJdGVtSWQ9Rkw2NDY1OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTUxNjA2UFJfTkVXU19VU1BSX19fX19GTDY0NjU4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=FL64658&amp;Transmission_Id=202601151606PR_NEWS_USPR_____FL64658&amp;DateId=20260115"/></p>

顛覆生物技術：Jurek Kozyra 推出 DNA 納米機器人，有望治癒那些被認為無法治癒的疾病